Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
B. Forey, J. Hamling, P. Lee, N. Wald.
International smoking statistics.
Oxford: The Wolfson Institute of Preventive Medicine, (2002),
[2.]
A.E. Cavelaars, A.E. Kunst, J.J. Geurts.
Educational differences in smoking: international comparison.
BMJ, 320 (2000), pp. 1102-1107
[3.]
E. Fernández, A. Schiaffino, M. García, E. Saltó, J.R. Villalbí, J.M. Borras.
Prevalencia del consumo de tabaco en España entre 1945 y 1955. Reconstrucción a partir de las encuestas Nacionales de Salud.
Med Clin (Barc, 120 (2003), pp. 14-16
[4.]
Ministerio de Sanidad y Consumo. Comparación de resultados ENSE 1987, 1993, 1995 y 1997. Salud de la población adulta (16 y más años). Madrid: Encuesta Nacional de Salud de España, 1999
[5.]
J.R. Banegas, L. Díez, F. Rodríguez-Artalejo, J. González, A. Graciani, F. Villar.
Mortalidad atribuible al tabaquismo en españa en 1998.
Med Clin (Barc, 117 (2001), pp. 692-694
[6.]
J. Marrugat, J. Sala, R. Masía, M. Pavesi, G. Sanz, V. Valle, et al.
Mortalilty differences between men and women following first myocardial infarction. RESCATE Investigators. Recursos Empleados en el Síndrome Coronario Agudo y Tiempo de Espera.
JAMA, 280 (1998), pp. 1405-1409
[7.]
M. Fiol, A. Cabades, J. Sala, J. Marrugat, R. Elosua, G. Vega, et al.
Variabilidad en el manejo hospitalario del infarto agudo de miocardio e España. Estudio IBERICA (Investigación, Búsqueda específica y Registro de Isquemia Coronaria Aguda.
Rev Esp Cardiol, 54 (2001), pp. 443-452
[8.]
J. González-Enríquez, T. Salvador-Llivina, A. López-Nicolas, E. Antón de las Heras, A. Musi, E. Fernández, et al.
Morbilidad, mortalidad y costes sanitarios evitables mediante una estrategia de tratamiento del tabaquismo en España.
Gac Sanit, 16 (2002), pp. 308-317
[9.]
E. Gil López, T. Robledo de Dios, J.M. Rubio Colavida, M.R. Bris Coello, I. Espiga López, I. Sáiz Martínez-Acitores.
Prevalencia del consumo de tabaco en los profesionales sanitarios.
Prev Tab, 2 (2000), pp. 22-31
[10.]
J.A. De Velasco, J. Cosín, J.L. López-Sendón, de E. Teresa, M. De Oya, G. Sellers, et al.
Nuevos datos sobre la prevención secundaria del infarto de miocardio en españa. resultados del estudio prevese II.
Rev Esp Cardiol, 55 (2002), pp. 801-809
[11.]
T.F. Van Berkel, H. Boersma, J.W. Roos-Hesselink, R.A. Erdman, M.L. Simoons.
Impact of smoking cessation and smoking interventions in patients with coronary heart disease.
Eur Heart J, 20 (1999), pp. 1773-1782
[12.]
Prevalencia y actitudes entre los médicos y otros profesionales de la salud en españa.
Manejo del fumador en la clínica, pp. 29-46
[13.]
A. Keys, H.L. Taylor, H. Blackburn, J. Brozek, J.T. Anderson, E. Simonson.
Coronary heart disease among Minnesota business and professional men followed 15 years.
Circulation, 28 (1963), pp. 381-395
[14.]
W.B. Kannel.
Some lessons in cardiovascular epidemiology from framingham.
Am J Cardiol, 37 (1976), pp. 269-282
[15.]
R. Doll, R. Peto.
Mortality in relation to smoking: 20 years’ observations on male british doctors.
BMJ, 25 (1976), pp. 1525-1536
[16.]
R. Doll, R. Gray, B. Hafner, R. Peto.
Mortality in relation to smoking: 22 years’observations on female british doctors.
Br Med J, 280 (1980), pp. 967-971
[17.]
S.M. Grundy, R. Pasternak, P. Greenland, S. Smith, V. Fuster.
Assessment of cardiovascular risk by the use of multiple-risk-factor assessment equations. a statement for healthcare professionals from the american heart association and the american College for Cardiology.
Circulation, 100 (1999), pp. 1481-1492
[18.]
US Department of Health and Human Services. Office of the Surgeon General. The health benefits of smoking cessation. A report of the Surgeon General. DHHS publication Nº (CDC):90-8416. Rockville: Department of Health and Human Services, 1990
[19.]
R.C. Pasternak, S.M. Grundy, D. Levy, P.D. Thompson.
Espectro de factores de riesgo para la arteriopatía coronaria.
Riesgo cardiovascular, pp. 30-31
[20.]
W.C. Willett, A. Green, M.J. Stampfer.
Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes.
N Engl J Med, 317 (1987), pp. 1303-1309
[21.]
C.M. Beard, T.E Kottke, J.E Annegers, D.J. Ballard.
The Rochester Coronary Heart Disease Project: effect of cigarette smoking, hypertension, diabetes and steroidal estrogen use on coronary heart disease among 40 to 59 year old women, 1960 through 1982.
Mayo Clin Proc, 64 (1989), pp. 1471-1480
[22.]
J. Perkins, T.B.S. Dick.
Smoking and myocardial infarction: secondary prevention.
Postgrad Med J, 61 (1985), pp. 295-300
[23.]
N.A. Rigotti, R.C. Pasternak.
Cigarette smoking and coronary heart disease.
Cardiol Clin North Am, 14 (1996), pp. 51-68
[24.]
E.J. Jacobs, M.J. Thun, L.F. Apicella.
Cigar smoking and death from coronary heart disease in a prospective study of US men.
Arch Intern Med, 159 (1999), pp. 2413-2418
[25.]
E. Prescott, H. Scharling, M. Osler, P. Schnohr.
Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. a 22 year follow up of 12419 men and women in the copenhagen heart study.
J Epidemiol Comm Health, 56 (2002), pp. 702-706
[26.]
J. He, S. Vuppturi, K. Allen, M.R. Prerost, J. Hughes, P.K. Whelton.
Passive smoking and the risk of coronary heart disease. a metaanalysis of epidemiologic studies.
N Engl J Med, 340 (1999), pp. 920-926
[27.]
H. Tunstall-Pedoe, C.S. Brown, M. Woodward, R. Tavendale.
Passive smoking by self report and serum nicotine and the prevalence of respiratory and coronary heart disease in the scotish heart health study.
J Epidemiol Community Health, 49 (1995), pp. 139-143
[28.]
W.B. Moskowitz, P.F. Schwart, R.M. Schiken.
Childhood passive smoking, race and coronary disease risk: the mCV twin study.
Arch Pediatr Adolesc Med, 153 (1999), pp. 446-453
[29.]
J.K. Ockene, L.H. Kuller, K.H. Svendsen, E. Meilahn.
The relatioship of smoking cessation to coronary heart disease and lung cancer in the Multiple Risk Factor Intervention Trial (MRFIT).
Am J Public Health, 80 (1990), pp. 954-958
[30.]
G. Rose, M. Shipley.
Plasma cholesterol concentration and death from coronary heart disease: 10 years results of the whitehall study.
Br Med J, 293 (1986), pp. 306-307
[31.]
M. Serrano, E. Madoz, I. Ezpeleta, B. San Julian, C. Amezqueta, J.A. Pérez Marco, et al.
Abandono del tabaco y riesgo de nuevo infarto en pacientes coronarios: estudio de casos y controles anidado.
Rev Esp Cardiol, 56 (2003), pp. 445-451
[32.]
B. Hermanson, G.S. Omenn, R.A. Kronmal, B.J. Gersh.
Beneficial sixyear outcome of smoking cessation in older men and women with coronary artery disease. results from the cass registry.
N Engl J Med, 319 (1988), pp. 1365-1369
[33.]
W.H. Herbert.
Cigarette smoking and arteriographically demostrable coronary artery disease.
Chest, 6781 (1975), pp. 49-52
[34.]
L.G. Escobedo, C.J. Caspersen.
Risk factors for sudden coronary death in the United States.
Epidemiology, 8 (1997), pp. 175-180
[35.]
A.P. Burke, A. Farb, G.T. Malcoim, Y.H. Liang, J. Smialek, R. Virmani.
Coronary risk factors and plaque morphology in men with coronary artery disease who died suddenly.
N Engl J Med, 336 (1997), pp. 1276-1282
[36.]
I.S. Ockene.
Smoking after acute myocardial infarction.
Circulation, 87 (1993), pp. 297-299
[37.]
R.T. Van Domburg, K. Meeter, D.F. Van Berkel, R.F. Veldkamp, L.A. Van Herweden, A.J. Bogers.
Smoking cessation reduces mortality after coronary artery bypass surgery: a 20 year follow up study.
J Am Coll Cardiol, 36 (2000), pp. 878-883
[38.]
D. Hasdai, K.N. Garrant, D.E. Grill.
Effect of smoking status on the long-term outcome after successful percutaneus coronary revascularización.
N Engl J Med, 336 (1997), pp. 755-761
[39.]
S.G. Gourlay, A.C. Rundle, H.V. Barron.
Smoking and mortality following acute myocardial infarction: results from the National Registry of Myocardial Infarction 2 (NRMI 2.
Nicotine Tob Res, 4 (2002), pp. 101-107
[40.]
R. Shinton, G. Beevers.
Meta-analysis of relation between cigarette smoking and stroke.
BMJ, 298 (1989), pp. 789-794
[41.]
K. Kubota, T. Yamaguchi, Y. Abe, T. Fujiwara.
Effects of smoking on regional cerebral blood flow in neurologically normal subjects.
Stoke, 14 (1983), pp. 720-724
[42.]
P.A. Wolf, R.B. D’Agostino, W.B. Kannel.
Cigarette smoking as risk factor for stroke. the framingham study.
JAMA, 259 (1988), pp. 1025-1029
[43.]
A. Planas, A. Clara, J. Marrugat, J.M. Pou, A. De Morner, C. Contreras, et al.
Age at onset of smoking is an independent risk factor in peripheral artery disease development.
J Vasc Surg, 35 (2002), pp. 506-509
[44.]
S. Wiseman, G. Kenchington, R. Dain, C.E. Marsall, C.N. McCollum, R.M. Greenhalg.
Influence of smoking and plasma factors on patency of femoropopliteal vein grafts.
BMJ, 299 (1999), pp. 643-646
[45.]
US department of educationwelfare: the health consequences of smoking report of the surgeon general.
Cardiovascular Disease,
[46.]
D. Hoffmann, E.L. Wynder.
Chemical constituents and bioactivity of tobacco smoke.
IARC Sci Publ, 74 (1986), pp. 145-165
[47.]
H.D. Wickramatillake, R.T. Gun, P. Ryan.
Carbon monoxide exposures in australian workplaces could precipitate myocardial ischaemia in smoking workers with coronary artery disease.
Aust N Z J Public Health, 22 (1998), pp. 389-393
[48.]
D.S. Celermajer, K.E. Soronsen, D. Georgakopoulos.
Cigarette smoking is associated with dose-related and pontentially reversible impairment of endothelium-dependent dilatation in healthy young adults.
Circulation, 88 (1993), pp. 2149-2155
[49.]
D.E Newby, R.A Wright, C. Labinjoh, C.A. Ludlam, K.A. Fox, N.A. Boon, et al.
Endothelial dysfunction, impaired endogenous fibrinolysis and cigarette smoking. A mechanism for arterial thrombosis and myocardial infarction.
Circulation, 99 (1999), pp. 1411-1415
[50.]
R.S. Stafford, C.G. Becker.
Cigarette smoking and atherosclerosis.
Atherosclerosis and coronary artery disease, pp. 303-325
[51.]
P. Cullen, H. Schulte, G. Assman.
Smoking, lipoproteins and coronary heart disease risk. Data from the Munster Heart Study (PROCAM.
Eur Heart J, 19 (1998), pp. 1632-1641
[52.]
R.W. James, I. Leviev, A. Righetti.
Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease.
Circulation, 101 (2000), pp. 2252-2257
[53.]
V. López García-Aranda, J.C. García Rubira.
Tabaco y enfermedad coronaria.
Cardiovascular Risk Factors, 9 (2000), pp. 408-416
[54.]
W.B. Kannel, R.B. D’Agostino, A.J. Belanger.
Fibrinogen, cigarette smoking and risk of cardiovascular disease: insigths from the Framingham Study.
Am Heart J, 113 (1987), pp. 1006-1010
[55.]
S. Gottlieb.
Some people are at very low risk from heart disease.
Br Med J, 319 (1999), pp. 1522
[56.]
N. Benowitz.
Pharmacologic aspects of cigarette smoking and nicotine addiction.
N Engl J Med, 319 (1988), pp. 1318-1330
[57.]
L. Tomás.
Efectos del tabaco sobre el sistema cardiovascular en hipertensos.
Tabaco, hipertensos y órganos diana, pp. 47-53
[58.]
B. Taylor, G.Y. Oudit, P.G. Kalman, P. Liu.
Clinical and pathophysiological effects of active and passive smoking on the cardiovascular system.
Can J Cardiol, 14 (1998), pp. 1129
[59.]
P.E. McBrigde.
The health consequences of smoking. Cardiovascular diseases.
Med Clin North Am, 76 (1992), pp. 333-353
[60.]
D. Magis, I. Geronooz, A.J. Scheen.
Smoking, insulin resistance and type 2 diabetes.
Rev Med Liege, 57 (2002), pp. 575-581
[61.]
J.K. Ockene, B.L. Shaten.
Cigarette smoking in the Multiple Risk Factor Intervention Trial (MRFIT). introduction, overview, method and conclusions.
Prev Med, 20 (1991), pp. 552-563
[62.]
Expert panel on detection evaluationtreatment of high blood cholesterol in adults. executive summary of the third report of the National Cholesterol Education Program (NECP).
JAMA, 285 (2001), pp. 2486-2497
[63.]
H. Schröder, J. Marrugat, R. Elosua, M.I. Covas.
Tobacco and alcohol consumption: impact on other cardiovascular and cancer risk factors in a southern european mediterranean population.
Br J Nutr, 88 (2002), pp. 273-281
[64.]
E. Barret-Connor, K. Tee Khaw.
Cigarette smoking and increased central adiposity.
Ann Inter Med, 111 (1989), pp. 783-789
[65.]
A.W. Gardner, P.S. Montgomery, C.J. Womack, L.A. Killewich.
Smoking history is related to free-living daily activity in claudicants.
Med Sci Sports Exerc, 31 (1999), pp. 980-986
[66.]
G. Lloveras, L. Barba Ribas, J.M. Ramon, L. Majem Serra, B. Vinas Roman.
Relación del consumo de alimentos y nutrientes con el hábito tabáquico.
Med Clin (Barc, 116 (2001), pp. 129-132
[67.]
R. Masiá, A. Pena, J. Marrugat, J. Sala, J. Vila, M. Pavesí, et al.
High prevalence of cardiovascular risk factors in girona, spain, a province with low myocardial infarction disease.
J Epidemiol Community Health, 15 (1988), pp. 507-515
[68.]
R. Li, E. Boerwinkle, A.F. Olshan, L.E. Chambless, J.S. Pankow, H.A. Tyroler, et al.
Glutathione s-tranferase genotype as a susceptibility factor in smoking-related coronary heart disease.
Atherosclerosis, 149 (2000), pp. 451-462
[69.]
X.L. Wang, H. Cai, G. Cranney, D.E. Wilcken.
The frecuency of a common mutation of the methionine synthase gene in the australian population and its relation to smoking and coronary artery disease.
J Cardiovasc Risk, 5 (1998), pp. 289-295
[70.]
M. Sentí, R. Elosua, M. Tomas, J. Sala, R. Masiá, J.M. Ordovas, et al.
Physical activity modulates the combined effect of a common variant of the lipoprotein lipase gene and smoking on serum triglyceride levels and high-density lipoprotein cholesterol in men.
Hum Genet, 109 (2001), pp. 385-392
[71.]
P.J. Talmud, S.R. Bujac, S. Hall, G.J. Millee, S.E. Humphries.
Substitution of asparagine for aspartic acid residue 9 (D9N) of lipoprotein lipase markedly augments risk of ischaemic heart disease in male smokers.
Atherosclerosis, 149 (2000), pp. 75-81
[72.]
S. Zhang, I. Day, S. Ye.
Nicotine induced changes in gene expression by human coronary artery endothelial cells.
Atherosclerosis, 154 (2001), pp. 277-283
[73.]
F.J. Schooten Van, A. Hirvonen, L.M. Maas, B.A. DcMol, J.C. Kleinjans, D.A. Bell, et al.
Putative susceptibility markers of coronary artery disease: association between VDR genotype, smoking and aromatic DNA adduct levels in human right atrial tissue.
FASEB J, 12 (1998), pp. 1409-1417
[74.]
X.L. Wang, J. Wang, D.E. Wilcken.
Interactive effect of the p53 gene and cigarette smoking on coronary artery disease.
Cardiovasc Res, 35 (1997), pp. 250-255
[75.]
X.L. Wang, A.S. Sim, R.F. Badenhop, R.M. McCredie, D.E. Wilcken.
A smoking-dependet risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene.
Nat Med, 2 (1996), pp. 41-45
[76.]
X. Wang, D. Rainwater, J. VandeBerg, B. Mitchell, M. Mahaney.
Genetic contributions to plasma total antioxidant activity.
Arterioscler Thromb Vasc Biol, 21 (2001), pp. 1190-1195
[77.]
F. Piedrafita, R. Morlander, G. Vanasnt, E. Orlova, M. Pfhal, W. Reynolds.
An Alu element in the myeloperoxidase promoter contains a composite SP-1 thyroid hormone-retinoic acid response element.
J Biol Chem, 271 (1996), pp. 14412-14420
[78.]
H.E. Montgomery, P. Clarkson, O.M. Nowose.
The acute rise in plasma fibrinogen concentration with exercise is influenced by the 453 polymorphism of the B-fibrinogen gene.
Arterioscler Thromb Vasc Biol, 16 (1996), pp. 386-391
[79.]
E.M. Sellers, R.F. Tyndale, L.C. Fernanades.
Decreasing smoking behaviour and risk through CYP2A6 inhibition.
Drug Discov Today, 8 (2003), pp. 487-493
[80.]
M.C. Fiorore, W.C. Bailey, S.J. Cohen, S.F. Dorfman, M.G. Goldstein, E.R. Gritz, et al.
Treating tobacco use and dependence.
Clinical Practice guideline,
[81.]
C.A. Jiménez-Ruiz, M. Barrueco, S. Solano, M. Torrecilla, F. Domínguez, J.L. Díaz-Maroto, et al.
Recomendaciones en el abordaje diagnóstico y terapéutico del tabaquismo. documento de consenso.
Prev Tab, 4 (2002), pp. 147-155
[82.]
J. Prochazka, C. DiClemente.
Stages and process of self-change of smoking: towards an integrative model of change.
J Clin Psychol, 3 (1983), pp. 390-395
[83.]
K.O. Fagerstrom, N. Schnieder.
Measuring nicotine dependence: a review of the FTND.
J Behav Med, 12 (1989), pp. 159-182
[84.]
J. Jarvis, M.A.H. Rusell.
Expired air CO: a simple breath of tobacco smoke intake.
Br Med J, 281 (1980), pp. 484-485
[85.]
N.J. Wald, S. Howard, P.G. Smith, K. Kjeldsen.
Association between atherosclerotic disease and carboxyhaemoglobin levels in tobacco smoke.
Br Med J, 3 (1973), pp. 761-765
[86.]
Silagy C. Physician advice for smoking cessation. Cochrane Library. N2, Oxford: update software, 2001
[87.]
Lancaster T, Tead LF. Individual behavioural counselling for smoking cessation. Cochrane Library N2; Oxford. Update software, 2001
[88.]
C.A. Jiménez-Ruiz, J. Ayest, M.A. Planchuelo, R. Abéngozar, M. Torrecilla, A.M. Quintas, et al.
Recomendaciones de la sociedad española de especialistas en tabaquismo para el tratamiento farmacológico del tabaquismo.
Prev Tab, 3 (2001), pp. 78-85
[89.]
N. Rigotti.
Treatment of tobacco use and dependence.
N Engl J Med, 346 (2002), pp. 506-512
[90.]
T.F. Van Berkel, H. Boersma, D. De Baquer, J.W. Deckers, D. Wood.
Registration and management of smoking behaviour in patients with coronary heart disease. the eurospire survey.
Eur Heart J, 20 (1999), pp. 1630-1637
[91.]
A. Mangas, D. Biedma, A. Macias, A. Barba.
El tabaco como factor de riesgo vascular. medidas terapéuticas.
Clin Invest Arterioscl, 13 (2001), pp. 122-128
[92.]
R.I. Richmond, L.A. Kehoe, I.W. Webster.
Multivariate models for predicting abstention following intervention to stop smoking by general practitioners.
Addiction, 88 (1993), pp. 1127-1135
[93.]
J.M. Lightwood, S.A. Glantz.
Short-term economic and health benefits of smoking cessation.
J Am Col Cardiol, 96 (1997), pp. 1089-1096
[94.]
M.C. Weinstein, W.B. Stason.
Cost-effectiveness of interventions to prevent or treat coronary heart disease.
Annu Rev Public Health, 76 (1986), pp. 1009-1013
[95.]
US Dept of Health and Human Services. The Health Benefits of Smoking Cessation. A report of the Surgeon General. USDHHS, Centers for disease Control. Office of Smoking and Health. 1990. DHHS Publication (CDC) 90-8416
[96.]
J. Marrugat, P. Solanas, R. D’Agostino, L. Sullivan, J. Ordovas, F. Cordón, et al.
Estimación del riesgo coronario en España mediante la ecuación de framingham calibrada.
Rev Esp Cardiol, 56 (2003), pp. 253-261
[97.]
J. Toledo.
Planes de tabaquismo: una realidad.
Prev Tab, 4 (2002), pp. 117-119
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.